CLGN241220C2500
- 0.00
- 0.000.00%
Collplant Newsroom
H.C. Wainwright Maintains Collplant(CLGN.US) With Buy Rating, Maintains Target Price $11
CollPlant Initial Breast Implant Data 'Encouraging,' Says H.C. Wainwright
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript Summary
CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript
Express News | D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target
CollPlant Biotechnologies Analyst Ratings
Express News | Collplant Biotechnologies' Cash And Cash Equivalents As Of September 30, 2024 Were $15.4M, Expected To Provide Cash Runway Until The End Of 2025
CollPlant Biotechnologies Q3 2024 Adj EPS $(0.33) Misses $(0.28) Estimate, Sales $4.00K May Not Be Comparable To $416.00K Estimate
Collplant Biotechnologies 3Q Rev $4,000 >CLGN
Collplant Biotechnologies 3Q Loss/Shr 38c >CLGN
Press Release: COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Earnings Scheduled For November 27, 2024
Earnings Preview: Collplant to Report Financial Results Pre-market on November 27
Companies Like CollPlant Biotechnologies (NASDAQ:CLGN) Can Afford To Invest In Growth
3D Bioprinting Market Industry Trends and Global Forecasts, 2019, 2024 and 2035 Featuring Key Players - 3D Systems, Cellink, CollPlant, Organovo, Rokit Healthcare, Stratasys, UPM Biomedicals - ResearchAndMarkets.com
CollPlant Shareholders Approve Key Proposals
CollPlant (CLGN), Stratasys Initiate Study for Breast Implants
Cracking The Code: Understanding Analyst Reviews For CollPlant Biotechnologies
H.C. Wainwright Maintains Collplant(CLGN.US) With Buy Rating, Maintains Target Price $11